Integrated Multi-Tissue Omics Identifies Acylcarnitine Accumulation as Shared Metabolic Marker of Diabetic Microangiopathy With Cross-Organ Validation
Investigative Ophthalmology & Visual Science · 16.09.2026 · 67 (11) · 31
DOI: 10.1167/iovs.67.11.31 ↗Kurz gefasst
Fachartikel in der Zeitschrift Investigative Ophthalmology & Visual Science, erschienen am 16.09.2026. Verfasst von Qian Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Carnitine, Diabetes Mellitus, Experimental, Diabetic Angiopathies, Diabetic Retinopathy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Purpose
Diabetic retinopathy (DR) is often recognized as a marker of systemic microvascular disease, but the metabolic links to other complications, such as diabetic nephropathy (DN), remain unclear. We aimed to identify systemic metabolic signatures shared by DR and DN and investigate their potential causal mechanisms.
Methods
Multi-tissue metabolomic profiling of the retina, plasma, and kidney was performed in streptozotocin-induced diabetic mice. Clinical relevance was supported by public human DR and DN transcriptomic datasets. Causal relationships were assessed by two-sample Mendelian randomization (MR) using eQTLGen and genome-wide association study (GWAS) summary statistics. Single-cell in silico perturbation analysis was performed to predict organ-specific functional consequences.
Results
Cross-organ metabolomic profiling identified a conserved systemic lipotoxic signature, yielding a predictive plasma panel comprised of free carnitine and two long-chain acylcarnitines. Clinical transcriptomics and MR analyses pinpointed the synchronous downregulation of the SLC22A5 and CPT2 axis as a causal genetic signature of this lipid imbalance. Furthermore, in silico single-cell analyses revealed that this shared metabolic disturbance induced distinct transcriptional responses across tissues, suggesting tissue-specific molecular responses that may contribute to organ-specific microvascular dysfunction.
Conclusions
Both DR and DN are associated with systemic disruption of acylcarnitine metabolism. A circulating carnitine/acylcarnitine signature may serve as a non-invasive indicator of microvascular risk, and the SLC22A5-CPT2 axis represents a potential therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai, China.
- The Affiliated Eye Hospital, Nanjing Medical University, Nanjing, China.
- Department of Ophthalmology, The Second Affiliated Hospital of Nantong University, Nantong, China.
- Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zitieren
APA
Liu, Q., Liu, Y., Yang, X., Liu, T., Zhao, Y., Xia, J., Fu, X., Yao, M., Wang, Y., Jiang, Q., & Yan, B. (2026). Integrated Multi-Tissue Omics Identifies Acylcarnitine Accumulation as Shared Metabolic Marker of Diabetic Microangiopathy With Cross-Organ Validation. Investigative Ophthalmology & Visual Science, 67(11), 31. https://doi.org/10.1167/iovs.67.11.31
Vancouver
Liu Q, Liu Y, Yang X, Liu T, Zhao Y, Xia J, et al. Integrated Multi-Tissue Omics Identifies Acylcarnitine Accumulation as Shared Metabolic Marker of Diabetic Microangiopathy With Cross-Organ Validation. Investigative Ophthalmology & Visual Science. 2026;67(11):31. doi:10.1167/iovs.67.11.31
BibTeX
@article{Liu2026,
author = {Liu, Qian and Liu, Yan and Yang, Xiongyi and Liu, Tianyi and Zhao, Ya and Xia, Jiao and Fu, Xueyun and Yao, Mudi and Wang, Yufan and Jiang, Qin and Yan, Biao},
title = {Integrated Multi-Tissue Omics Identifies Acylcarnitine Accumulation as Shared Metabolic Marker of Diabetic Microangiopathy With Cross-Organ Validation},
journal = {Investigative Ophthalmology & Visual Science},
year = {2026},
volume = {67},
number = {11},
pages = {31},
doi = {10.1167/iovs.67.11.31}
}
EUVIMED